Spyglass Pharma, Inc. (NASDAQ:SGP) Given Consensus Rating of “Moderate Buy” by Brokerages

Posted by on Jun 14th, 2026

Spyglass Pharma, Inc. (NASDAQ:SGP – Get Free Report) has received an average recommendation of “Moderate Buy” from the six research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $45.00.

Several brokerages have recently issued reports on SGP. Stifel Nicolaus began coverage on shares of Spyglass Pharma in a research note on Tuesday, March 3rd. They set a “buy” rating and a $42.00 price objective for the company. Leerink Partners cut shares of Spyglass Pharma to a “market perform” rating in a research note on Tuesday, March 3rd. Citigroup began coverage on shares of Spyglass Pharma in a research note on Tuesday, March 3rd. They set a “buy” rating and a $42.00 price objective for the company. Zacks Research raised shares of Spyglass Pharma to a “hold” rating in a research note on Wednesday, March 4th. Finally, Jefferies Financial Group began coverage on shares of Spyglass Pharma in a research note on Tuesday, March 3rd. They set a “buy” rating and a $62.00 price objective for the company.

Read Our Latest Stock Report on SGP

Institutional Trading of Spyglass Pharma

A number of institutional investors have recently added to or reduced their stakes in the business. First Light Asset Management LLC purchased a new stake in Spyglass Pharma during the 1st quarter worth $9,716,000. Affinity Asset Advisors LLC purchased a new stake in Spyglass Pharma during the 1st quarter worth $6,478,000. Monashee Investment Management LLC purchased a new stake in Spyglass Pharma during the 1st quarter worth $2,461,000. Bank of America Corp DE purchased a new stake in Spyglass Pharma during the 1st quarter worth $726,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Spyglass Pharma during the 1st quarter worth $308,000.

Spyglass Pharma Price Performance

Shares of NASDAQ SGP opened at $18.44 on Friday. Spyglass Pharma has a 52-week low of $17.60 and a 52-week high of $32.44. The company’s fifty day moving average is $21.99.

Spyglass Pharma (NASDAQ:SGP – Get Free Report) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.02).

About Spyglass Pharma

(Get Free Report)

We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).

Read More

Analyst Recommendations for Spyglass Pharma (NASDAQ:SGP)

Receive News & Ratings for Spyglass Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyglass Pharma and related companies with MarketBeat.com's FREE daily email newsletter.